Last reviewed · How we verify

Clonazepam/Placebo levetiracetam IV

Assistance Publique - Hôpitaux de Paris · Phase 3 active Small molecule

Clonazepam/Placebo levetiracetam IV is a Benzodiazepine (clonazepam) and pyrrolidine derivative (levetiracetam) Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 3 development for Acute seizure management or status epilepticus (inferred from IV formulation and trial design). Also known as: Association of placebo to an active comparator (clonazepam).

Clonazepam enhances GABAergic inhibition in the central nervous system to reduce seizure activity, while levetiracetam modulates neuronal excitability through an unknown mechanism, and this trial compares clonazepam/placebo with IV levetiracetam.

Clonazepam enhances GABAergic inhibition in the central nervous system to reduce seizure activity, while levetiracetam modulates neuronal excitability through an unknown mechanism, and this trial compares clonazepam/placebo with IV levetiracetam. Used for Acute seizure management or status epilepticus (inferred from IV formulation and trial design).

At a glance

Generic nameClonazepam/Placebo levetiracetam IV
Also known asAssociation of placebo to an active comparator (clonazepam)
SponsorAssistance Publique - Hôpitaux de Paris
Drug classBenzodiazepine (clonazepam) and pyrrolidine derivative (levetiracetam)
TargetGABA-A receptor (clonazepam); SV2A and calcium channels (levetiracetam, partially characterized)
ModalitySmall molecule
Therapeutic areaNeurology
PhasePhase 3

Mechanism of action

Clonazepam is a benzodiazepine that potentiates GABA-A receptor signaling, increasing chloride influx and neuronal hyperpolarization to suppress seizure propagation. Levetiracetam's exact mechanism remains unclear but involves modulation of synaptic vesicle proteins and neuronal calcium channels. This Phase 3 trial appears to evaluate the comparative efficacy and safety of these agents, likely in acute seizure management or status epilepticus.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Clonazepam/Placebo levetiracetam IV

What is Clonazepam/Placebo levetiracetam IV?

Clonazepam/Placebo levetiracetam IV is a Benzodiazepine (clonazepam) and pyrrolidine derivative (levetiracetam) drug developed by Assistance Publique - Hôpitaux de Paris, indicated for Acute seizure management or status epilepticus (inferred from IV formulation and trial design).

How does Clonazepam/Placebo levetiracetam IV work?

Clonazepam enhances GABAergic inhibition in the central nervous system to reduce seizure activity, while levetiracetam modulates neuronal excitability through an unknown mechanism, and this trial compares clonazepam/placebo with IV levetiracetam.

What is Clonazepam/Placebo levetiracetam IV used for?

Clonazepam/Placebo levetiracetam IV is indicated for Acute seizure management or status epilepticus (inferred from IV formulation and trial design).

Who makes Clonazepam/Placebo levetiracetam IV?

Clonazepam/Placebo levetiracetam IV is developed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).

Is Clonazepam/Placebo levetiracetam IV also known as anything else?

Clonazepam/Placebo levetiracetam IV is also known as Association of placebo to an active comparator (clonazepam).

What drug class is Clonazepam/Placebo levetiracetam IV in?

Clonazepam/Placebo levetiracetam IV belongs to the Benzodiazepine (clonazepam) and pyrrolidine derivative (levetiracetam) class. See all Benzodiazepine (clonazepam) and pyrrolidine derivative (levetiracetam) drugs at /class/benzodiazepine-clonazepam-and-pyrrolidine-derivative-levetiracetam.

What development phase is Clonazepam/Placebo levetiracetam IV in?

Clonazepam/Placebo levetiracetam IV is in Phase 3.

What are the side effects of Clonazepam/Placebo levetiracetam IV?

Common side effects of Clonazepam/Placebo levetiracetam IV include Sedation/drowsiness, Dizziness, Ataxia, Behavioral changes, Respiratory depression (clonazepam).

What does Clonazepam/Placebo levetiracetam IV target?

Clonazepam/Placebo levetiracetam IV targets GABA-A receptor (clonazepam); SV2A and calcium channels (levetiracetam, partially characterized) and is a Benzodiazepine (clonazepam) and pyrrolidine derivative (levetiracetam).

Related